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ABSTRACT 
katG is tbe sole gene encoding for catalase peroxidase enzyme in 
Mycobacterium tuberculosis enabling its survival in the host macrophage. This same 
gene has been indicted to play an important role in forming the killing effect of 
isoniazid (INH), a major drug used in the treabnent of tuberculosis (TB)~ It has been 
indicated that the folDlation of new generation drugs for TB will be connected to 
further understanding this interaction and the study of the structures of the katG 
gene. 
The high molecular weight genomic DNA of Mycobacterium tubercuJ.o.,;., of 
the clinical strain MTB69/03 from HUSM has successfully been isolated tbroogb a 
modification of the method in D. van Soolingen et. al .. Two primers with extra sites 
for tbe excision sites of EcoRl and Hind/11 were successfully used to produce a 
DNA product of 2252 base pairs. The product was then inserted into a pCR®.2.l-
TOPO® plasmid vector. The insert was continued by the use of both PCR and 
restriction enzymes. 
Tite successfully confinned inserted plasmids were then sent for sequencing. 
ABSTRAK 
katG merupakan gen tunggal bagi enzim katalase dan peroksidase dalam 
Mycobacterium tuhercu/t.Jsis dan berfungsi dalam membo]ehkan organisma tenebut 
hidup dalam makrofaj perumab. Gen tersebut tmut memainkan peranan peoting 
dalam kesam membunuh isoniazid (INH) yang merupakan drug peoting da1am 
mengubati kes--kes tuberculosis (TB). Kajian telah menunjukkan babawa 
pengbasilan drug TB yang bam akan bergantung pada pemabaman tentang stmktm 
katG dan interaksi katG dan INH. 
DNA genomik Mycobacterium tuberculosis yang mempunyai berat molekul 
tinggi telah diasingkan dari strain klinikal MTB69/03 yang diperolehi dari HUSM. 
Teknik yang digmmkan adalah modifikasi tek:nik yang ditunjukkan dalatn o_ van 
Soolingen et. al .. Dua primer yang mempunyai kawasan pemotongan untuk EcoRl 
and Hindi// telah digunakan dan telah berjaya menghasilkan produk DNA yang 
sebeSar 2252 pasangan bes. Produk tersebut dimasukkan ke dalam vektor plasmid 
pCR®2.1-TOPD®· Konformasi kemasukkan primer yang betul dilakukan meJaui 
PCR dan menggunakan enzim 
Plasmid yang telah dipastikan betul dimasukkan produk kemudiaonya 
dihantar untuk pendudukan. 
1.0 INTRODUCTION 
1.1 Tuberculosis(TB) 
Tuberculosis is a disease that bas long plagued man for many centuries. The 
earliest known name of this disease is Phthisis (''to waste") by the Greeks. It has also 
been known as consumption in the 1800s, wasting disease, and the white pJague. 
This disease is known as the leading cause of death :from a single infectious agen~ 
with a prevalence of greater than 1.6 billion people (Whitney and Wainberg, 2002). 
Until the mid-1800s, people thought that tuberculosis, or TB, was hereditaty. In 
1865 a French sw-geon, Jean-Antoine Villemin, proved that TB was contagious, and 
in 1882 a Qennan scientist named Robert Koch discovered the bacterium that causes 
T8
7 
Mycobacterium tuberculosis. 
TB is caused by an organism called Mycobacterium tubercu/osi:r (MfB) also 
sometimes called as the tubercle bacilli. It is a member of the genus mycobacterium 
which consists of members of the MTB complex and more than 80 species of non· 
tubercular myco{)acteria including pathogenic, opportunistic and ncm pathogenic 
species (Soini et al., 2001). Mycobacteria can cause a variety of diseases. Some 
mycobacteria are called tuberCUlous mycobacteria because they cause m or 
diseaSes similar to TB. These mycobacteria are MTB, M. bovis, and M. t:ifricanum. 
d bac 
.. l>t"i~ are called non-tuberculous mycobacteria because they do not 
0 ter myco "' ....... 
TB On
e connnon type of nontuberculous mycobacteria isM avillm complex. 
cause · 
b I S 
mvcobacteria are not usually spread from person to person. 
Non-to ercu ou 'J 
TubefCUiosis (TB) is a communicable chronic granulomatous disease caused 
I 
___ .. nlly involves the lungs but may effect any other organ or tissue in the 
by MTB· t lJ:jlUI.I 
body (Kwnar, et al.,2003). Tuberculosis is nol'Dlally spread through airborne 
transmission of droplet nuclei containing the MTB bacili. A majority of cases 
involves the lungs and is known as pulmonary tubemllosis where as exira 
pulmoruuy tuberculosis is due to the infection of other parts of the bmnan body. 
About 80-90% of tuberculosis involves pulmonmy tuberculosis and 10-200.4. 
involves extra pulmonary tUberculosis. 
1.2 Epidemiology 
There is archaeological evidence that tuberculosis has been occuning in 
human population for over 3000 years. This disease has been docmnented in 
analyses of mummies and skeletons which show defonnities and lesions similar tQ 
that of a TB patient. Among the places that this evidence bas been fuund include 
North Africa, Europe and even the Americas. There is no evidence of tuberculosis in 
sub-Saharan Afti~ East Asia, or the Pacific until after contact was initiated with the 
Europeans, during the period of colonization (Aeras, 2005). 
Tubercu1osis grew to epidemic proportions in Europe beginning in the early 
l600's as populations shifted to expanding cities and population densities incnzed. 
The worsenin8 of the enviromnental factors due to pollution, the degradation of 
sanitation due to tbe mass tranSlocation as well as the huge collection of individnals 
there lead to the spread ofTB. Tuberculosis came to be the leading cause of death in 
western Europe in the 18th and early 19th centuries (Whitney and Wainbecg, 2002). 
In the 1 cjh centurY there was a decline in tuberculosis that was accelerated by 
the development of effective chemotherapy for tuberculosis in the secoad half of the 
20
1tt CentWY (.Aeras,2005). One explanation of this decline is the rise in economic 
,., 
conditions and the improvements in sanitation. Another reason might have been the 
segregation of individuals infected with TB from the general public via the use of 
sanatorimns. In the less industrialized parts of the world, the increase in tuberculosis 
occurred much later but was later halted by improving conditions in health and 
standards of living as well as the development and use dispersion ofTB vaccines. 
Unfortunately, this trend bas been shown to be reversed. The World Health 
Organization (WHO) bas reported that there are more than 8 million new cases of 
active disease each year and that 3 million people die annually from tubercuJosis. 
The prevalence of TB is estimated to be over 1.6 billion people and is the cause of 
7% of all death in developing countries (Rouse et al., 1995). People in higb risk 
groups in acquiring this disease are patients coinfected with HIV, prison inmates, 
and professionals who work with people in these high risk groups (O"Brien et a/., 
1995). 
A model by Dye C. in his publication Epidemiology, in Clinical 
Tuberculosis, 3nl Edition show that tuberculosis is on the increase and that the 
number of cases grew 1. 7% per year from 1997 to 2000 and that with the pn:sent 
trends there wi11 be 9-10 million new cases in 2010 (Aeras, 2005). The rise in TB 
infection could be attributed to four main factOIS. Firstly is the impact of HIV/ AIDS 
. h urun·es were the epidemics co-exist. HIV infection rates among TB cases 
mt ose co 
exceed 
60
% in south Africa, Zimbabwe and Zambia Second, the impact of 
J
• . ublt·c health infrastructure in the world may via the worsening urban 
dectnlng P 
social and economic conditions result in the TB has resurged in the past decade 
l 199
4) Third tbe mixing of prison with civilian populations and Jastly 
(Rouse et a ., · ' ' 
. ed surveillance and case reporting as other possible causes may be 
recent unpro¥ 
deteetin8 the uue prevalence of the disease. 
0 
Another further disturbing trend in the outbreak is the emergence of multi--
drug resistant strains of the Mycobacterium, MDR-MTB. An important reasoo for 
this trend is patient non-compliance and delays in obtaining susceptibility data 
which still continue to be a hindrance to the elimination and instead fiuther 
exacerbate the development of MDR-MTB (Peloq~ 1993). :rviDR TB has also 
been recognized as the cause of mortality for 70-90% of AIDS patients who develop 
TB (CDC, 2005) and the trend seems to be growing. WHO surveys report drug 
resistance in MTB isolates at rates of 1.7-36.90A. in aJJ 58 countries surveyed 
between 1996 and 1999. Mutants resistant to isoniazid (lNH) is recognized as the 
most preva1ent accolDlting for as much as 26% clinical MDR-MTB isolates in the 
USA (BaneJ.jee, 1994). 
1.3 Pathogenesis 
Tuberculosis (TB) is a communicable chronic granulomatous disease caused 
by Mycobacterium tuberculosis (MTB) (Kumar eta/., 2003). It is spread via droplet 
nuclei in the air are about 1 to 5 microns in diameter (CDC, 2005) and can remain 
suspended in the air for several hours, depending on the environment. When a 
person inhales air containing particles expelled by an infectious persoo,. most of the 
larger particles beCome lodged in the upper respiratozy tract, where infection is 
unlikely to develop. However, the droplet nuclei may reach the alveoli, where 
infection begins. (Figure 2). 
In, primaiY TB, an unsensitized individual or an individual never before 
ed th
e tn"cobacteria is infected by MTB. When MTB is inhaled and enters 
expos to 'J 
. alveoli the bacterium becomes aggressively attacked and engu]fed bv 
the lungs v1a ' J 
n 
macropbages. But where other bacteria succumb to the attack TB SUTVJ. th , ves e 
macrophage with the aid of the "oxidative burst" mechanism which is due to the 
effects of superoxide dismutase and catalase-peroxidase which are enzymes that 
scavenge the oxygen radicals used as killing mechanisms by the macropbages. The 
TB will then be taken up by the alveolar macrophage and multiply in them. Once the 
mycobacteria gains entry into the macrophage, it inhibits normal bacteriacidal 
effects by manipulation of endosomal pH and arresting endosomal maturation 
(Kumar eta/., 2003). 
A small amount of the TB bacilli will spread through the regional lymph 
nodes and then through the bloodstream to more distant tissues and organs including 
areas such as kidneys, bmins and bone. Within 2 to 10 weeks after infection, the 
immune system usually intervenes. The immune response of hypersensitivity and 
resistance to the organism halts the multiplication of the tubercle bacilli and prevents 
further spread. In these instances, inflammatory conditions consolidate around the 
area of the MTB infection known as the Ghon focus which is also followed by tissue 
necrosis and scarring. This series of scarred tissue and consolidated cells are known 
as Gohn's complex. During this time, the patient usually doesn't suffer any 
symptoms other than a slight fever due to the infection. In this instance, the TB 
infection may resolve itself but usually, the complex may harbour viable MTB 
which may survive for years before being reactivated in secoodaty lesions. 
In certain cases the disease may progress as progressive primary 
tubefCOiosis. This occurs when the MTB overcomes the defenses of the immune 
systeJll and begin to multiply. This occurs in inummocompromised individuals or as 
the result of impainnent in the defence mechanisms. The risk: may be approximately 
3 
times greater with diabeteS to more than 100 times greater for HIV infected 
10 
persons compared to those who do not have the disease (CDC, 2005). Other forms 
of this state are due to substance abuse, renal disease, neoplasia and hematological 
disorders. 
Another scenario is when secondary TB infection or reactivation TB occurs. 
This is due to the reactivation of dormant primary lesion due to weakness of host 
resistance as well as exogenous reinfection of the host In approximately 5% of 
persons who have been infected with MTB, TB disease will develop in the first or 
second year after infection. In another 5%, disease will develop later in their lives. 
The remaining 90% will stay infected, but :free of disease, for the rest of their Jives 
(CDC, 2005). This can occur within the lung or in other distant organs because of 
dissemination and seeding of the MTB into surroiDlding tissue via blood and the 
lymphatics. About 80-90% of TB involves puhnonary TB and 10-200/o involves 
extra pulmonatY TB (Kumar et al., 2003). In extra pulmonary TB,. the infection 
occurs in lungs, tarynx, lymph nodes, brain, kidneys, bones or joints. 
As the infection progresses, the infection causes localized damage to the 
tissue and then systemic damage. The majority of the infedion which begins with 
putmonatY TB will cause progressive erosion into 1he bronchus of the tung forming 
cavities in the tung and the fonnation of fibrous tissue. V"m tbe cavity tbe MfB can 
be disseminated into tbe air via the airways as well as via sputum. High amounts of 
sputum, mucoid in the beginning and later purulent will appear fullowed by 
hemoptysis. 
Througb the airways and through the lymphatic and vascular channels,. the 
. 
1 
multiplying MTB, may then cause military TB in which the MTB can 
progreSSive Y 
. ut into the blood stream and go to the heart where it is distnbuted to the 
then draJJl 0 
. ll ,,er the body. Almost every organ of the body can then be seeded bv 
artenes a Ov' J 
11 
, , sp een, adrenal, MTB foci. It is most prominent however in the liver bone 1 
meninges, kidneys, fallopian tubes and epidedymis (Kumar et al., 2003) . 
. . . · .. : . ·.··. . . ' 
. ..... ~ . . : " 
.. ,_ .. : ·.: · .. 
·; t' -=;.:r; :.:. 4 ~· • 
·. ·: ;: ·<·· ~~· ... , .. ~.._, .. ;. ~ 
• I • ••t • • • • 
.. .. .... . 
Special 
Exposure 
) 
immuno cells t.--_,...---l 
-.~~- form a hard 
shell (in this 
example, 
bacilli are in 
the lungs) 
Secondary 
Infection 
Hardshell 
breaks down 
and tubercle 
bacilli escape 
and muHiply (in 
this example, 
TB disease 
develops In the 
lungs) 
Miliary 
TB 
) 
Figure 
1
: A chart depicting the pathogenesis of Mycobacterium Tuberculosis (CDC, 200S) 
1.4 control and Prevention 
Because of this of the slow growth rate of the causative agent, isolation and 
identification, and drug susceptibility testing of this organism can take several weeks 
or longer (Soini et a/., 2001). A complete medical evaluation for TB includes a 
medical history, a physical examination, a Mantoux tube.Jculin skin test, a chest 
. h and any appropriate bacteriologic or histologic examin ations 
radiograP ' · 
1'l 
To date only 9 drugs have been approved by the FDA for the treatment of 
tuberculosis infections. Very few experimental drugs are available (Peloquin, 1993) 
and most of these drugs have been extensively used for the treatment of the disease. 
Due to the highly contagious and very stubborn nature of the disease, the treatment 
usually includes combinations of these drugs. The most prescribed form of treabnent 
is that of the Arkansas regimen from the Unites States. It is a short course treatment 
is 6-9 months long and is only possible when isolates remain susceptible to both 
isoniazid and rifampin (Peloquin, 1993 ). The first line of drugs used in the fight 
against TB are isoniazid, rifampin, pyramidazole and ethambutol. The second line 
drugs or drugs used to complement these drugs include capreomycin, cyclosaine, 
ethionamide, kanamycin, and the fluoroquinoles. 
Initially, TB was in a decline especially in the developing countries. This 
was due mainlY to the use of mass vaccination as wen as improving public 
healthcare, treatment and the decline of poverty. Unfortunately, the trend shifted 
especially seen in the United States in the early 80s. This was mainly due to 
co infection with the HIV virus (Haeym et a/., 1994 ). Another major n:ason for this 
. th 
3
nnearance of multidrug resistant strains of MTB, MDR-MTB These 
nse was e ·Yr~ • 
. h .. ued nreat resilience against the drugs used for tbe treatmenl against TB 
straWS S On· tr· ' 
. rtality rates significantly higher than that of drug sensitive strains (O~brien 
bavmgmo 
eta/., 1996). 
In tine with these trends. the WHO bas been aaively pursuing stqtS in 
eradicating this meoace. It jntroduced DOTS (directly observed tbempy, short 
d b 
strm-TB Partnership, which encompassed proper handling of the 
course) an t e vr 
e
nt and overall reporting of the disease through passive case-
rusease,managetn 
ttnent of the cases. It was based on the believe that proper 
finding and trea 
1'l 
prescription and implementation of proper chemotherapy combining isoniazid, 
rifampin, pyrazinamide and ethambutol could eventually prove to be the answer 
(Haeym eta/., 1994). Unfortunately, patient non-compliance, rising poverty and rise 
in drug resistance continue to be the main problems in the treatment of the disease. 
A cure-rnte of over 90% is possible with this approach and Dye notes that the 
average treatment success rate was 82% in 155 national programs (Aeras, 2005). 
However, coverage is far from complete and at the current rates of DOTS expansion 
the target of70% case detection will not be reached until after 2010 (Aeres, 2005). 
1 .. 5 katG gene 
katG is a gene with is 2223 bp in size which encodes the catalase peroxidase 
enzyme in MTB (Ng et al., 2004) and is imperative in conferring a selective 
advantage on the MTB by possibly enabling it to withstand hostile environments 
(HaeYm et at., 1995). This heme-containing enzyme is part of a group of proteins 
known as bydroperoxidase I (HPJ) or catalase peroxisdase group (DeVito & Morris, 
2002
). The HPI protein is a bifunctional protein made out of catalase which turns 
hydrogen peroxide into water and oxygen (2H2~H20 + 02) Peroxidase on the 
other hand accepts protons to tum hydrogen peroxide into water (H2(h~H2_0) 
(Haeym & Cole, 1997)-
The significance ofkatG was highlighted by Zhang et al, when it was fuund 
that the deletion of this gene conferred isoniazid resistance)NHR toM tuherr:ulosis 
. 
1 
aJ 1995). Isoniazid (INH) was ftrSt .reported to be effective ~maincl (O'Bnen e ., .. 
MTB in 
1952 
and has been playing a pivotal role in the fight against TB since then 
d t 1 
J995). This drug is actuaUy a prodru& and has been shown to be 
(QuemaJi e a ., 
1..4 
very effective against MTB with an MIC as low as 0.02pg/pl (Haeym et al., 1992). 
The function is essential in the use of present trea1ments against TB. Altbougb used 
extensively, the exact mechanism of action of this drug has still eluded us. Studies 
by J.A. Ainsa et a/. (2001 ), and Wimpenny, ( 1967) that the enzyme produced by the 
katG gene activates the INH and is reacted once again before it becomes a fonn 
toxic to MTB. This new toxic form will then bind to the NADH and the complex 
then inactivates inhA, a gene that shares similar expression fac.."tors as katG. This is 
tum effects the action of the type II fatty acid synthase (F ASII) impairing 
biosynthesis of mycolic acid and distrupts the cell wall production of the MfB 
(Ainsa et a/.,2001). The katG protein has also been suggested to aid in tbe transport 
ofiNH into the cell (Rouse & Morris, 1995). Figure 3 contains an outline diagram 
of all the many theories put forth on the mechanisms ofkatG and its association with 
INH. 
INH resistant strains of MTB make up 25% of most identified MTB strains. 
60-70% of INH resistant strains have been linked to defects in katG gene. (Whitney 
& Wainberg, 2002) Patients infected with this strain showing this kind of resistance 
show poor prognosis with 46% of patients who undergo treabnent having failures of 
relapses (Quemmd eta/., 1995). Only about 50% will eventually be able to have 
negative sputum shedding of the virus (Goble, 1993). 
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Figure 2: The effects of katG and katG mutagens on Mycobacterisua tllberculosi:s survival with 
treatment with Isoniazid (JNH). 
1.6 Review of Literature 
Zhang et a/. (1992) demonstrated that INH resistance in some isolates was 
conferred by a total gene deletion of the katG gene which encodes catalase-
peroxidase activity (O'Brien, 1995). This has Led to the further understanding of the 
ftmctions of isoniazid (INH) tl1at had up till tl1en been a mystery. 
Haeym et ai. (1993) in the characterization study ofkatG, concluded that the 
enzyme produced by katG interacts with INH and converts it into a toxic derivative 
which is acted upon by a second unknown mechanism. This study was expanded by 
Ainsa et al. (2001), and Wimpenny, (1967) that each concluded that the enzyme 
produced by the katG gene activates the INH and undergoes another reaction before 
it becomes a toxic form to MTB. With this a basic theoty on the worlrings on the 
INH action was founded. 
Pym eta/., (2001) in their study of the regulation and virulence of katG and 
its promoters concluded that antimycobacterial activi1y ofiNH is limited by the rate 
of activation and not interaction with other cellular processes. Thus, INH analogues 
was the rational strategy for a new generation INH-based drugs. 
DeVito & Morris (2002) in studying the sbuctures of the katG gene fotmd 
that a rational design of INH-based analogues is difficult because katG protein 
crystal structure and tertimy and quartenary structural determinants still remained 
unknown. 
Recently the genome of the MTB laboratory strain H37RV was completely 
sequenced (GenBank accession no. NC 000962) and allows for better research and 
understanding of the relationship of the genes. 
Due to these findings, it can be concluded that the structure of katG is an 
important detenninant in finding an alternative cure for TB in the near future .. The 
isolation and expression of the katG gene is possible and has been perfOrmed .. The 
molecular structures and structural determinants can now be studied to further 
expand on the present knowledge on the interactions of katG with isoniazid and the 
killing effects. This would allow better understanding on ways to deal with the TB 
epidemic and enable the rational design of INH-based derivatives/analogues which 
will be more effective than INH. 
1'7 
1.7 Objectives 
Although the katG gene has been cloned and the sequence is known, the 
structure of this enzyme, ltowever, has yet to be elucidated. The objective of this 
study is to clone the katG gene which will later be used to express the enzyme for 
study of the protein structure by X-ray crystallisation. 
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1.7 Flowchart of Project 
PCR ofkatG gene from genomic Mycobacteriwn tuherculosi..•• 
DNA 
A-Tailing ofPCR Product 
Cloning into plasmid vector pCR®2. 1-TOPO® 
TranasfOimation into competent cells (TOPJO) 
Selection of positive clones 
Characterization of 
Recombinant plasmid by 
PCR 
Characterization of 
recombinant plasmid by 
Restriction Enzyme analysis 
Gene of interest (katGl gene) 
2252kb 
Final Characterization by 
Sequencing 
Figure 3: A Flowchart to outline the steps involved to be accomplished in the 
experiment 
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2.0 MATERIALS 
2.1 Reagents and Chemicals 
No Reagents and Chemicals Supplier 
l 7H9 Middle Brooke Pifco Lab, USA 
2 OADC enrichment media Becton Dickinson & Co., 
USA 
3 Sodium pyruvate lOOmMIL Bio-Rad, USA 
4 Trisbase Amres Co. ®11 USA 
5 EDTA Promega, USA 
6 Lysozymes Merck, Germany 
7 Sodium dodecyl sulphate Bio-Rad, USA 
8 Protinasek Invitrogen, USA 
9 Sodium chloride (NaCl) Merck, Gemany 
10 N-acetyl-N,N,N-trimethylammonium Sigma, USA 
bromide 
(CTAB) 
11 Isoamyl-alcohol BDHAnalar 
12 Chlorofonn M&B Laboratmy 
13 Isopropanol Merck, Germany 
14 70%ethanol Merck, Germany 
15 Sodium Hydroxide (NaOH) Merck, Germany 
16 Glacial acetic acid Bio-Rad,USA 
17 Agarose Promega, USA 
18 OrangeG Sigma, USA 
19 Etbidium bromide Sigma, USA 
20 Sucrose AnalaR®, Gennany 
21 Tryptone Pronidasa, Madrid 
22 Yeast extract Pronidasa, Madrid 
23 E. coli (TOPI 0), -70°C · Invitrogen, USA 
24 Magnesium chloride (MgCh) AualaR®, Gennany 
25 Calcium chloride (CaCh) AnaJaR®, Gennany 
26 Glycerol tO% Sigma, USA 
27 Kanamycin Pmmega, USA 
28 X-Gal Promega, USA 
29 Lambda DNA/ Hind Ill marker Promega, USA 
30 1 OObp DNA ladder Promega, USA 
31 Blue/Orange 6x Loading Dye Promega, USA 
2.2 Kits 
No. Kits Supplier 
1 Taq DNA Polymerase: Fennentas, USA 
Taq DNA Polymerase 
1 Ox Reaction Buffer 
MgCh 
dNTPmix 
2 Pfu DNA Polymerase: Fennentas, USA 
Pfu DNA Polymerase 
1 Ox Reaction Buffer 
"'l1 
MgS04 
dNTPmix 
3 Taq DNA Polymerase: Promega, USA 
Taq DNA Polymerase 
1 Ox Reaction Buffer 
MgCh 
dNTPmix 
4 QIA Quick® Gel Extraction kit QIAGEN, USA 
5 TOPO® Cloning Reaction Jmritrogen, USA 
pCR®2.1-TOPO® vector 
salt solution 
6 QIAprep® Miniprep QIAGEN, USA 
7 EcoRl Restirction Enzyme Fennentas, USA 
EcoRI restriction enzyme 
lOx buffer 
2.3 Equipment 
No. Equipment Supplier 
1 Dragon 3002 Ana1ytica1 Balance Mettler Toledo, Canada 
2 Cyberscan 1000 pH meter Eutec~ UK 
3 TBVX Hexmnix Water Bath Heto-High Teclmology, 
Scandinavia 
4 Innova 4080 Rotary Shaker New Bntnswick 
ScientificCnmc.USA 
5 Pipettes Eppendorf, Germany 
6 Eppendorf Fixed Angle Rotar Microcentrifuge Eppendorf AG, 
Oennany 
7 Refrigerated Centrifuge 581 OR Eppendorf: C.~ermany 
8 Gene AMP PCR System 9700 Thermal cycler Applied 
Biosyste~USA 
9 PTC-200 DNA Engine (Peltier TheiDlal MJ Research, USA 
Cycler) 
10 Super Showerwave Microwave Oven Sanyo, 
11 Agarose Gel Electrophoresis Apparatus CBS Scientific Co.~USA 
12 Elite300Plus Wealtec, USA 
13 UVP Bioimaging UVP Image Analyzer Lab Compani~USA 
14 UV -25 UV Transilluminator Hoefer, UK 
15 Nanodrop ™ ND-1 00 Spectrophotometer NnanodropTM,USA 
16 Shaking Incubator SI600 Lab Companion, USA 
17 Microbiological Incubator Binder, Germany 
18 Lambda EZ 150 UV-Vis Spectrophotomer Perkin Elmer,USA 
3.0 PREPARATION OF REAGENTS 
3.1 Preparation of 7H9 Middle Brooke broth 
7H9 Middle Brooke broth was prepared by dissolving 2.35g of the powdered 
broth in 450mL deionised distilled water. 19.09mL sodium pyruvate 100 mM/L 
which has been filtered prior to use is then pipetted. The solution is then mixed 
thoroughly and aliquoted into flasks. 50 mL OADC enrichment media is then added 
to the solution prior to use. 
3.2 Preparation of 10xTE buffer 
1 Ox TE buffer was prepared from the adding 12_lg of Tris in pH8.0 with 
3.7g 1mM EDTA. The pH was adjusted with sodium hydroxide. Deionised distilled 
water was then added to make up the solution to a level of 100 mL. The solution was 
autoclaved at 121 oc for 15 minutes and stored at room temperature. 
3.3 Preparation of 10mg/mL lysozymes 
The lysozymes are prepared into concentrations of 1 OmglmL by adding 0.1 g 
of the powdered lysozymes provided with 10 mL deionised distilled water. The 
solution is then thoroughly mixed and filter sterilised prior to use. 
3.4 Preparation of 10o/o SDS (sodium dodecyl sulphate) 
The 10% SDS is by adding lOg of sodium dodecyl sulphate in powder form 
into 1 OOmL of distilled water. The solution is then dissolved by heating at 650C for 
20 minutes. The solution is not autoclaved. The solution may then be kept at room 
temperature for not longer than I month. 
3.5 Preparation of Protinase k (1mg/mL) 
Protinase k ( 1 mg/mL) was prepared by dissolving 1 Omg of protinase k in 
IOOmL distilled water. The solution was then mixed properly and filter sterilized. 
The solution was then stored in small aliquots at -20°C for not more than 1 year .. 
3.6 Preparation of CT AB/NaCI solution 
CT AB/NaCl solution is prepared by dissolving 4.1 g of sodimn chloride and 
10 g N-acetyi-N,N,N-trimethylammonium bromide (CTAB) in 80mL of deionised 
distilled water. The solution is then stirred on a heater block. Deionised dislilled 
water is then added up to 100 mL. The complete solution is then autoclaved at 
121 oc for IS minutes. 
3.7 Preparation of isoamyl-alcohol (24: 1) 
Isoamyl and alcohol in of 24: I is prepared by adding 4 mL of the isoamyl-
alcohol with 9 mL of chlorofonn. The solution was then mixed thoroughly and then 
stored in a dark bottle. 
3.8 Preparation of Sodium Hydroxide (NaOH) 1M 
JM sodium hydroxide was prepared by dissolving 12g ofNaOH in 300 mL 
deionised distilled water. The solution was autoclaved at 121 °C for IS minutes and 
stored at room temperature. 
3.9 Preparation of SOx TAE (Tris-Acetate) Buffer 
The SOx T AE buffer is prepared by adding 121 g ofTris base in 50 mL O.SM 
EDT A at pH 8.0. IM Sodium hydroxide is added to adjust the pH to 8.0. 28. 55 mL 
of glacial acetic acid is then added to the solution. The solution is then mixed on a 
heated plate with a stirrer. Deionised distilled water is then added to the solution to 
make up to SOOmL. The solution is thoroughly mixed with a stirrer. The media was 
autoclaved at 121 oc for IS minutes. The solution is used as a stock solution fur the 
preparation of lx T AE buffer which is prepared by adding lOmL 50x T AE buffer 
with deionised distilled water to make up 500 mL. 
3.10 Preparation of Orange G loading buffer 
Orange G is prepared by diluting 0.0625g Otange Gin powder form in 25 
mL distilled water. lOg sucrose is then added to the solutioa The solution is then 
thoroughly mixed. 
3.11 Stock Solution of Ethidium bromide 
Ethidium bromide was prepared by diluting lg of ethidium bromide into 
1000 mL deionised distilled water. The solution was then stored in a dark bottle with 
warning signs. 
3.12 Preparation of Luria-Bertani (LB) agar 
LB agar was prepared by dissolving 15g tryptone, Sg of yeast extract, JOg of 
NaC1 and 15g of agar into 750 mL of deionised distilled water. The pH was adjusted 
to 7.2 with 1M NaOH. Deionised distilled water was added to make the final volume 
of 1000 mL. The media was autoclaved at 121 oc fur 15 minutes. The media was 
cooled down before the apropiate antibiotic was added. 10 pL of kanamycin 50 mgl 
f.lL may be added to produce LB agar with kanamycin. The agar was stored in the 
cold room. 
3.13 Preparation of Luria Bertani (LB) broth 
LB broth was prepared by 15g tryptone, Sg of yeast extract and lOg ofNaCl 
into 750 mL of deionised distilled water. The pH was adjusted to 12 with 1M 
NaOH. Deionised distilled water was added to make the final volume of 1000 mL. 
The media was left to cool before being aliquoted into universal bottles. The media 
was autoclaved at 121 °C for 15 minutes and stored at room temperature. 
3.14 Preparation of Competent cells 
E. coli competent cells were prepared by first cultming the cells in I 0 mL of 
LB (Luria-Bertani) broth. The culture was then incubated at 37°C with vigorous 
shaking at 180 rpm horizontally in the shaking incubator overnight. 100 1J.L of the 
overnight culture was then aliquoted and inserted into another 10 mL of LB broth. 
The culture was incubated at 37°C in the shaking incubator. The optical density of 
the culture was observed every half an hour with a spectrophotometer at wavelength 
of600nm. When the culture showed an OD of0.W.5, the culture was then chi11ed 
on ice for 10 minutes. The culture was then centrifuged at 3000tpm for 10 minutes 
at a temperature of 4°C. The supernatant produced was discarded and the pellets 
were resuspended with 6mL of cold 100 mM magnesium chloride (MgCh)4 The 
cells were then chilled on ice for 45 minutes. The ceJis were centrifuged again at 
3000rpm for I 0 minutes at a temperature of 4°C. The supernatant produced was 
once again discarded. The remaining pellets were resuspended in 400 mL of cold 
100 mM calcium chloride (CaCh). 60 J.1L of 10% glyceroJ was then added to the 
'lO 
cells. 50 J.lL of the suspension was then aliqouted into 1.5 mL microcentrifugetubes 
and stored at -70°C. 
3.15 Preparation of Kanamycin stock (50mglml) 
Kanamycin stock was prepared by adding 10 mg of kanamycin sulphate into 
10 mL deionised distilled water. The mixture was filtered using 0..2 J.Ull filter 
memebrane prior to use. The solution was aliquoted for .into quantities of lmL and 
stored in microcentrifuge tubes at -20°C. 
3.16 Preparation of 1 OObp DNA ladder 
1 OObp DNA ladder was prepared by adding 50 pL of 1 OObp DNA ladder 
with Blue/Orange 6x loading buffer in a microcentrifuge tube. The mixture was then 
mixed properly and stored at 4 OC. 
3.17 Preparation of Lambda DNA/ Hind Ill marker 
Lambda DNA/ Hind III marker was prepared by adding 50JL L of Lambda 
DNN Hind III marker with Blue/Orange 6x loading buffer in a microcentrifuge 
tube. The mixture was then mixed properly and stored at 4 OC. 
'lO 
4.0 GENERAL METHOD 
4.1 Isolation of high molecular weight genomic DNA from 
mycobacteria. 
This method was a modified version of the isolatioo technique described by 
van Soolingen eta/. (1991 ). Mycobacterium tuberculosis samples were first cultured 
in 7H9 broth and incubated at 37°C for 2 weeks. 1.0mL of each culture was placed 
into a microcentrifuge tube. The sample is then heated at 80°C for 20 minutes in the 
water bath. This step was used to kill the cells in the sample. The culture was spun in 
a microcentrifuge at 12000 rpm for 5 minutes. The resulting supernatant was then 
discarded with the use of a micropippette. The pellet was then resuspended with 
500J1L 1x TE buffer by means ofvortexing. SO J1L 10mglmL lysozymes was then 
added to the solution. The sample was then mixed via vortexing and then incubated 
at 37°C for 1 hour in the water bath. This process allowed tbe lysozyme to break the 
cell walls. 70J.IL of 10% SDS (sodium doda.-yl sulphate) and 6 J.1L of lOmglmL 
proteinase K were then added to the sample to digest the proteins in the sample. The 
sample was then vortexed for about 10 seconds to mix and then incubated at 650C 
for 10 minutes. 100 J1L of 5M NaCI was then added to 1he sample and mixed by 
vortexing for 30 seconds. 80 J1L of prewanned CT AB/NaCl solution was added to 
the sample. The sample was then mixed via vortex till the sample became creamy or 
milky white. The sample was then incubated at 65°C fur 10 minutes. An equal 
amount of chlorofonn/isoamyl chlorofonn (24:1) which equals to 700 pL was then 
added to the sample and then mixed with the use of a vortex for I 0 seoonds. The 
sample was then centrifuged at room temperature for 5 minutes at 12000 1pm. 600 
'll\ 
